Amorfix reports new finding for vCJD blood screening assay and provides corporate update

    TSX: AMF

    TORONTO, Sept. 12 /CNW/ - Amorfix Life Sciences, a company focused on
treatments and diagnostics for brain wasting diseases, today reported that its
EP-vCJD(TM) Blood Screening Assay can detect sporadic Creutzfeldt-Jakob
Disease (sCJD) prions using brain material spiked into human plasma at the
same sensitivity.
    "sCJD is the most common form of this brain wasting disease and has a
profound impact on health care because of its potential for patient to patient
transmission," noted Dr. Neil Cashman, Chief Scientific Officer of Amorfix.
"An antemortem diagnostic test for sCJD would be an important step forward in
managing the risk from this disease in health care settings."
    This finding supports Amorfix's platform technology for detecting
aggregated misfolded proteins and expands the potential use of the assay to
sCJD. The company is seeking to acquire blood and spinal fluid from sCJD
patients to assess whether the assay can be used for antemortem diagnosis of
this disease. Sporadic CJD occurs spontaneously in the worldwide population
with an estimated 6,000 new cases per year and there are only post-mortem
diagnostic tests available.
    The company also reported that, other than as a result of generally
adverse market conditions, the company is not aware of any reason for the
recent decline in its share price. The company continues to advance its
business plan for both diagnostic and therapeutic products as outlined in
previous announcements.

    About Amorfix

    Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing
therapeutic products and diagnostic devices targeting brain-wasting diseases
including ALS, Alzheimer's Disease, Parkinson's Disease and variant
Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection(TM)
(EP) technology enables it to specifically identify very low levels of
aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated
misfolded proteins are a common element of many brain wasting diseases and the
ability to identify AMPs and understand their structure and mechanism of
folding are the first steps to developing new treatments for these devastating
diseases. Amorfix's lead programs are a diagnostic blood screening test for
vCJD and a therapy for ALS.

    This information release may contain certain forward-looking information.
Such information involves known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements to be
materially different from those implied by statements herein, and therefore
these statements should not be read as guarantees of future performance or
results. All forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently available to
it as well as other factors. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks and
uncertainties identified by the Company in its public securities filings,
actual events may differ materially from current expectations. The Company
disclaims any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or

    %SEDAR: 00022789E

For further information:

For further information: Dr. George Adams, President & Chief Executive
Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6959, Fax: (416) 847-6899,; James Parsons, Chief Financial Officer, Amorfix Life
Sciences Ltd., Tel: (416) 847-6929, Fax: (416) 847-6899,

Organization Profile

Amorfix Life Sciences Ltd.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890